Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00001582 · ClinicalTrials.gov registry record
Investigation of the Human Immune Response in Normal Subjects and Patients With Disorders of the Immune System and Cancer
A clinical trial, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- 902
- Enrollment target
NCT00001582: Completed study, sponsored by National Cancer Institute (NCI).
NCT00001582 is a clinical trial that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 902 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00001582 has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- 902 participants
- Enrollment target
Study Summary
This protocol is being submitted to consolidate, update, and expand two previously approved protocols (77-C-0066 and 82-C-0044) into a single protocol. The purpose of this study is to examine the factors involved in the regulation of the immune system of healthy individuals and to define the abnormalities in this regulation that underlies the immunological disorders of patients with a variety of immunodeficiency and malignant disorders. The studies will include the ex vivo phenotypic and functional analysis of the network of cells involved in humoral and cellular immune responses, and in vivo testing for the capacity to make delayed-type hypersensitivity and humoral responses following immunization with a variety of antigens. Individuals to be studied will include patients with a variety of malignancies and patients with primary and secondary immunodeficiency disorders. Selected family members or family members known to be genetic carriers of certain immunodeficiency diseases as well as normal, unrelated individuals will also be studied. A small number of procedures will be used including analysis of blood obtained by phlebotomy, apheresis, skin testing and recall antigens and immunization to assess humoral immunity....
Primary Outcome
No statistical endpoints are identified for this study; the purpose of the study is to acquire information regarding various immunodeficiency syndromes, HTLV-1 infection and malignancies. The data collected will not be combined for a summary report of the entire study; however, reports for specific disease entities may be published.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 902 participants |
| Start Date | 1997-06-07 |
| Est. Completion | 2023-03-17 |
What the finished NCT00001582 record still lists
NCT00001582 is an observational study that tracks outcomes without assigning an intervention. The registered 902 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT00001582 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00001582 about?
NCT00001582 is a clinical study titled "Investigation of the Human Immune Response in Normal Subjects and Patients With Disorders of the Immune System and Cancer". This protocol is being submitted to consolidate, update, and expand two previously approved protocols (77-C-0066 and 82-C-0044) into a single protocol. The purpose of this study is to examine the factors involved in the regulation of the immune system of healthy individuals and to define the abnorma...
What is the current status of trial NCT00001582?
This trial is currently completed. The enrollment target is 902 participants. The study started on 1997-06-07. Estimated completion is 2023-03-17.
Who is sponsoring clinical trial NCT00001582?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05769777 · 901 participants · Phase 2
Open Label, Long-term Study Evaluating Safety and Efficacy of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis
- NCT02352116 · 900 participants · NA
Evaluation of Post-PACU Pain Management in Pediatric Surgery
- NCT02414347 · 900 participants
F 18 T807 Tau PET Imaging of Alzheimer's Disease
- NCT02670408 · 900 participants
Diagnostic and Therapeutic Applications of Microarrays in Heart Transplantation
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI